Sandoz has completed the acquisition of U.S. dermatology company Fougera Pharmaceuticals for $1.5 billion in cash. Fougera has dermatology development and manufacturing expertise, particularly in the area of semi-solid forms such as creams and ointments, as well as a branded business, PharmaDerm.   “We are pleased to combine Fougera’s strong portfolio and pipeline of dermatology medicines with Sandoz’s existing global leadership positions in biosimilars and generic injectables, ophthalmics and a...